APD 209

Drug Profile

APD 209

Alternative Names: ADE CTP-12-001; APD-209; Trisialic acid compound

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adenovir Pharma
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Infectious keratoconjunctivitis

Most Recent Events

  • 29 Apr 2016 Adenovir Pharma completes a phase IIa trial in Infectious keratoconjunctivitis in Germany, Poland and Germany(Ophthalmic)
  • 19 Feb 2016 Adenovir Pharma has patent protection for APD 209 in Russia
  • 27 Nov 2015 Phase-II clinical trials in Infectious keratoconjunctivitis in Poland (Ophthalmic) (EudraCT2012-005694-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top